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Abstract
Background: People with bipolar disorder (BD) have a mortality gap of up to 20 years compared to the general
population. Physical conditions, such as cardiovascular disease (CVD) and cancer, cause the majority of excess deaths
in psychiatric populations and are the leading causes of mortality in people with BD. However, comparatively little
attention has been paid to reducing the risk of physical conditions in psychiatric populations. Unhealthy lifestyle
behaviors are among the potentially modifiable risk factors for a range of commonly comorbid chronic medical
conditions, including CVD, diabetes, and obesity. This systematic review will identify and evaluate the available
evidence for effective interventions to reduce risk and promote healthy lifestyle behaviors in BD.
Methods/design: We will search MEDLINE, Embase, PsychINFO, Cochrane Database of Systematic Reviews, and
CINAHL for published research studies (with at least an abstract published in English) that evaluate behavioral or
psychosocial interventions to address the following lifestyle factors in people with BD: tobacco use, physical inactivity,
unhealthy diet, overweight or obesity, sleep-wake disturbance, and alcohol/other drug use. Primary outcomes for the
review will be changes in tobacco use, level of physical activity, diet quality, sleep quality, alcohol use, and illicit drug
use. Data on each primary outcome will be synthesized across available studies in that lifestyle area (e.g., tobacco
abstinence, cigarettes smoked per day), and panel of research and clinical experts in each of the target lifestyle
behaviors and those experienced with clinical and research with individuals with BD will determine how best to
represent data related to that primary outcome. Seven members of the systematic review team will extract data,
synthesize the evidence, and rate it for quality. Evidence will be synthesized via a narrative description of the behavioral
interventions and their effectiveness in improving the healthy lifestyle behaviors in people with BD.
(Continued on next page)
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Discussion: The planned review will synthesize and evaluate the available evidence regarding the behavioral or
psychosocial treatment of lifestyle-related behaviors in people with BD. From this review, we will identify gaps in our
existing knowledge and research evidence about the management of unhealthy lifestyle behaviors in people with BD.
We will also identify potential opportunities to address lifestyle behaviors in BD, with a view to reducing the burden of
physical ill-health in this population.
Systematic review registration: PROSPERO CRD42015019993
Keywords: Bipolar disorder, Risk, Prevention, Mania, Depression, Tobacco, Smoking, Physical activity, Sleep, Diet,
Weight loss, Alcohol/other drug use, Interventions, Treatment, Morbidity, Mortality
Background
People with mental illness have a reduced life ex-
pectancy of between 12 and 20 years compared to the
general population [1, 2]. To date, much of the attention
on this issue has focused on the increased risks of
suicide in people with mental illness, which has been
shown to account for about 20 % of the premature
deaths in populations with a mental illness. Compara-
tively little attention has been paid to reducing the risk
of physical conditions, which account for 80 % of excess
deaths in psychiatric populations [2].
A particular focus on bipolar disorder (BD) is import-
ant. In BD, reduced life expectancy in comparison with
the general population ranges from 11 to 20 years
depending on the age of onset of the disorder [3]. The
reasons for this disparity are complex and multi-faceted,
involving genetic, biological, environmental, psycho-
logical, and social factors. Cardiovascular disease (CVD)
diagnoses occur 6 years earlier for those with BD than
for depression and 15 years ahead of the general popula-
tion [4]. Many factors are attributed to this, including
the significant and adverse effects of medication for BD,
such as weight gain, metabolic syndrome, high cho-
lesterol, hypertriglyceridemia, and other cardiometabolic
problems [5]. Medications commonly prescribed in
BD—anti-manic, antipsychotic, and antidepressant treat-
ments—can negatively contribute through adverse side
effects including weight gain, sedation, and disordered
glucose tolerance [6]. In addition, the phases of BD
mean that people can oscillate between intense periods
of severe depression (with high risk of suicide) followed
by intense periods of activity and irritability, masking a
cycle of agitation, sleep, and physical exhaustion that
can have a significant impact on confidence, self-
efficacy, and health-related decisions [7]. Up to 65 % of
people with BD report current tobacco use [8] and
smoke at 2.6 times the rate of people with major
depressive disorder (MDD) and 6.3 times more than the
general population [9]. Smoking is independently
associated with suicide risk, poorer response to treat-
ment, and structural brain changes [10]. Physical in-
activity has been identified as an independent predictor
of premature mortality among people with BD and sig-
nificantly increases their risk of CVD [11]. In a study of
1046 Australian women, poor diet quality was associated
with twice the odds for BD [12]. In another study com-
paring 2032 participants with BD in the general popula-
tion, having BD was associated with significantly poorer
eating behaviors, including fewer daily meals and diffi-
culty obtaining or cooking food, as well as increased ap-
petite and caloric intake [13]. Complicating this and
supporting an integrated approach, people at risk for
one adverse health behavior are at greater risk for others
[14]. There is often poor integration between mental
health and physical health services internationally and
well-documented concerns by people with mental illness
using existing services, who report inequity of access to
physical-health-related interventions and support [9].
Together, the periods of being unwell with a psychiatric
illness, combined with side effects of many medications,
may contribute to the inequality in physical wellness
for clients with mental health issues and the general
population.
In order to reduce the mortality gap between people
with BD and the general population, greater under-
standing is required of how best to assist them and their
clinicians to address the potentially modifiable lifestyle
behaviors associated with this gap [15, 16]. Recently, the
International Society for Bipolar Disorder (ISBD) devel-
oped consensus guidelines for monitoring of adverse
side effects associated with commonly prescribed medi-
cations for the disorder [17]. The aim for these guide-
lines was to increase the acknowledgement and focus of
health care providers on the physical health comor-
bidities germane to the management of BD [17]. Whilst
this is critically important to the field, reducing the
medication load for people with BD is just one strategy
in addressing the mortality gap associated with the
condition [18].
Of additional importance is to identify acceptable and
effective interventions to improve the health outcomes
of people with BD. There is increasing recognition of the
importance of supporting all people with mental health
problems to focus on lifestyle factors, such as smoking
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cessation, in addition to symptom management [19].
However, the nature of BD may mean that additional
strategies are indicated to ensure safety and well as effi-
cacy of these approaches. In contrast to other mental
disorders, for example, regulation and structure are crit-
ical in BD for both symptom and lifestyle management.
For example, when depressed, strategies need to encour-
age stimulation and activation; however, when manic,
the opposite is true [20]. Key withdrawal symptoms of
nicotine are insomnia and increased appetite, with
standard behavioral programs recommending increased
physical activity to cope with cravings, stress, and weight
gain [21]. Sleep disturbance, increased appetite, and ex-
cessive exercise are all critical warning signs for a relapse
to BD [22], and thus careful strategies for self-regulation
may be a unique feature of any program that recom-
mends changing these behaviors in people with BD. To
date, no systematic review has examined these issues or
the available evidence to support lifestyle management
in people with BD specifically.
The objective of this review is to systematically identify
and evaluate the literature regarding lifestyle behavioral
interventions among people with BD. We aim to
synthesize the available evidence regarding the manage-
ment of unhealthy lifestyle behaviors and the promotion
of health behaviors in people with BD, with regard to
the impact of such interventions on health, symptoms,
and related outcomes. Specifically, we aim to answer the
following questions:
a) Which, if any, interventions have demonstrated
effectiveness in the treatment of tobacco use,
sleep-wake disturbances, alcohol/other drug use, or
in encouraging healthy eating or healthy levels of
physical activity for people with BD?
b) Do any integrated evidence-based interventions
exist that target a range of lifestyle behaviors within
one package for people with BD? If so, do these
integrated treatments produce improvements across
all of the treatment targets?
c) Have any lifestyle-based interventions been tested
in people with BD that incorporate eHealth (and
related technologies)? If so, how have outcomes
compared with face-to-face delivered interventions?
Methods
This systematic review is registered with the International
Prospective Register of Systematic Reviews (PROSPERO,
http://www.crd.york.ac.uk/PROSPERO, registration number:
CRD42015019993). The protocol has been written accord-
ing to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses-Protocol (PRISMA-P) recommenda-
tions for systematic review protocols [23], and the findings
will be reported using PRISMA guidelines [24].
Criteria for study inclusion
To be eligible for inclusion in the planned review,
articles will be required to describe an intervention con-
ducted in people with BD aged 18 years and over. Any
type of behavioral or psychosocial intervention will be
considered; however, articles must report at least one
behavioral health or lifestyle outcome (e.g., smoking,
alcohol or other substance use, diet, physical activity,
sleep). Additionally, eligible articles will be required to
report their results for participants with bipolar disorder
separately to any other participants in the study, be
published in a peer-reviewed journal, and published in
English (at least an abstract). Randomized trials as well
as uncontrolled trials including cohort, historical, and
case-control studies will be considered. Our primary
outcomes of interest will be the following lifestyle behav-
ior outcomes: tobacco use, physical activity, diet quality,
sleep quality, alcohol use, cannabis use, and illicit drug
use from baseline to the last available follow-up. Second-
ary outcomes of interest will include participants’ psy-
chiatric symptoms and physical health outcomes such as
changes in quality of life scores, depression, manic
symptoms, body mass index, and other CVD risk factors
from baseline to the last available follow-up as available.
Search strategy for identification of studies
We will search the following electronic databases to
identify potentially eligible studies for inclusion in the
review: MEDLINE, Embase, PsychINFO, Cochrane
Database of Systematic Reviews, and CINAHL. The
search will be limited to human research and those with
at least an abstract written in English. No date restric-
tions will be placed on the searches, and search terms
will be intentionally kept broad and general to increase
the likelihood of capturing potentially eligible studies.
An example of the proposed search strategy for
MEDLINE is outlined in Table 1.
Data extraction
Following de-duplication of the search results, two team
members (LT and FK-L) will independently review the
titles and abstracts of all returned articles to identify
studies that potentially meet the inclusion criteria. Poten-
tially eligible articles will then be reviewed in full by two
team members against the eligibility criteria (LT and
FK-L). Any disagreement between the team members re-
garding eligibility will be resolved through discussion with
a third reviewer (LS). Reasons why studies were excluded
from this phase of the search will be recorded.
Trial reports (e.g., from clinical trial registries) for
included studies will be reviewed to determine whether
outcomes of interest were assessed but not reported in the
identified publication. For older studies where trial regis-
tration was not mandatory, authors will be contacted to
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determine whether data on the outcomes of interest to
the review are available for provision to the systematic re-
view team. The abstracts of included studies not published
in full using English will be reviewed for potential for data
extraction.
Based on the results of the eligibility step, included
studies will be divided into categories, according to the
primary health behavior or lifestyle target of the intervention
(tobacco, physical activity, diet quality, sleep-wake disturb-
ance, and alcohol/other drugs). Included studies on weight
loss interventions will be reviewed for information about the
primary target of behavior within the weight loss interven-
tion (e.g., physical activity, diet). We expect that, within each
lifestyle intervention/behavior, a range of outcomes will be
reported (e.g., minutes or hours of moderate or vigorous ac-
tivity per day or week). We will extract data related to all re-
ported outcomes for each included study for this review.
Studies reporting more than one behavioral outcome will
contribute data to all relevant intervention analyses.
Data will be extracted from all eligible studies using a
data extraction form specifically developed for this study
(see Additional file 1). Extracted data will include study
design, study setting, sample size, study population and
participant demographics (including diagnoses), baseline
characteristics (including phase of bipolar disorder), re-
cruitment and retention rates (including completion),
Table 1 Search strategy using MEDLINE 1946 to present with
daily update
Number Searches Results
1 Bipolar Disorder/ 33,501
2 bipolar*.tw. 43,114




7 (mixed adj (state* or episode*)).mp. [mp = title,
abstract, original title, name of substance word,
subject heading word, keyword heading word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
1096
8 Cyclothymic Disorder/ 565
9 cyclothymi*.tw. 751
10 rapid next cycl*.tw. 0
11 schizoaffective.tw. 4195




14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
or 12 or 13
117,677
15 Smoking/or Marijuana Smoking/or Smoking
Cessation/
137,906
16 "Tobacco Use"/ 394
17 (smok* or tobacco or cigarette* or nicotine).tw. 244,392
18 exp Alcohol Drinking/ 55,319
19 alcoholic intoxication/or alcoholism/ 78,084
20 (alcohol* or drinking).tw. 281,327
21 marijuana abuse/or exp opioid-related disorders/ 24,563
22 Cannabis/ 7067
23 designer drugs/or exp street drugs/ 10,732
24 exp Sleep/ 64,880
25 sleep.tw. 104,983
26 Exercise/or Exercise Therapy/ 101,251
27 Physical Exertion/ 53,748
28 Motor Activity/ 83,896
29 Sports/ 25,382
30 (Physical Education and Training).mp. [mp = title,
abstract, original title, name of substance word,
subject heading word, keyword heading word,
protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
12,568
31 exp Diet Therapy/ 44,656
32 (diet* adj5 (health* or weight*)).tw. 26,065
33 (calorie adj5 (control or reduc* or restrict*)).tw. 3102
34 food choice*.tw. 2516
35 (exercise* or sport*).tw. 232,095
36 (physical activit* or physical inactivit*).tw. 62,477
Table 1 Search strategy using MEDLINE 1946 to present with
daily update (Continued)
37 nutrition*.tw. 179,639
38 Sedentary Lifestyle/ 4056
39 (sedentary adj5 (lifestyle or behavio?r*)).tw. 4236
40 (weight adj (loss or reduc* or gain* or change*)).tw. 103,986
41 (drug adj (use* or abus*)).tw. 56,661
42 (diet* adj5 quality).tw. 4443
43 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or
32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40
or 41 or 42
1,374,954
44 random*.tw. 711,373
45 cross-over studies/or double-blind method/or
random allocation/or single-blind method/
248,804
46 Randomized Controlled Trial/ 404,345
47 Controlled Clinical Trial/ 89,970
48 trial.tw. 368,603
49 groups.tw. 1,376,585
50 (evaluation* or treatment* or intervention*).tw. 4,060,728
51 44 or 45 or 46 or 47 or 48 or 49 or 50 5,446,183
52 14 and 43 and 51 6410
53 limit 52 to english language 5828
NOTE: use of the * in this table is to ensure that all derivations of the search
term are captured in the search strategy
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details of the intervention, details of health behavior out-
comes (all reported timepoints), details of other reported
study outcomes (e.g., quality of life, BD symptoms), indi-
cators of acceptability to participants, and information
for the assessment of the risk of bias. All reported trial
outcomes related to the lifestyle behavior targeted by the
intervention will be extracted in the event that a study
does not report on the primary outcome for the review
but reports on a structurally/conceptually similar outcome
related to the primary outcome (possible reporting bias).
Seven review authors (LT, JL, FJ, TH, AT, SH, and
FK-L) will independently extract data from eligible
studies using the standardized form, with discre-
pancies identified and resolved through discussion
with an eighth team member (LS). Missing data will
be requested from study authors, who will be asked
to supply the missing information in de-identified,
summarized format. Included studies will be divided
between the five reviewers, such that each study has
data extracted by three reviewers.
The Cochrane Collaboration’s tool for assessing risk of
bias will be used to conduct a risk of bias (quality) as-
sessment for individual studies included in the review
[25]. As per this tool, criteria for judging risk of bias will
be applied (low, unclear, high) to the following domains:
selection bias (random sequence generation, allocation
concealment); performance bias (blindness of partici-
pants and personnel); detection bias (blindness and mo-
dality of outcome assessment); attrition bias (incomplete
outcome reporting); and reporting bias (selective out-
come reporting). A similar approach will be taken to
non-randomized studies included in the review, using
the eight-item Newcastle-Ottowa Scale as a guide [26].
To determine reporting bias, the ORBIT classification
system will be adopted [27] for each included study. In
each intervention category (tobacco, physical activity,
diet quality, sleep-wake disturbance, alcohol/other
drugs), a matrix will be constructed for included studies,
which evaluates the reporting of the primary outcome
for the review, and other trial outcomes related to that
lifestyle behavior. Each reported outcome will be given a
rating according to whether the primary outcome/other
outcome was reported in full (with statistical analysis
results reported in full), not reported at all, or partially
reported (e.g., only the p value was provided). For those
studies given a “partially reported” or “not reported”
rating for the given primary outcomes of interest, the
nine-point ORBIT classification system will be applied.
Each of these studies will be given a classification of A-I,
depending on the clarity with which the primary out-
come was measured and analyzed. Clarification will be
sought from trial registry information and/or study
authors to determine whether a study might be classified
as incomplete outcome reporting and at risk of outcome
reporting bias (due to a change in outcomes from regis-
tered details).
Primary outcomes
The primary outcomes for the review will be changes in
the lifestyle behaviors targeted by the intervention be-
tween baseline and the immediate post-intervention
follow-up assessment, namely tobacco use, levels of
physical activity, diet quality, sleep quality, alcohol use,
and illicit drug use. In order to synthesize results across
all included studies within a particular lifestyle behavior,
a review of reported outcomes for each included study
will be conducted by LT and FK-L to determine how the
primary outcome of interest is reported for each study
in each lifestyle area (e.g., abstinence rates for tobacco
use studies versus cigarettes per day, minutes of vigor-
ous exercise per week for physical activity studies versus
hours per week of non-leisure sedentary behavior).
Collaborating researchers specializing in each of the
lifestyle categories will be consulted during this process
to ensure that the primary outcome for each category
best represents the available data and is relevant and im-
portant to the field (tobacco = AB, FK-L, SW; physical
activity = RC, SD, SW; diet quality = FJ, AT, SW; sleep-
wake disturbance = NR, SH, TH, SW; alcohol/other
drugs = AB, FK-L, SW). SW, a consumer-researcher, will
review these primary outcomes for relevance and im-
portance to people experiencing BD.
Data analysis
The primary analysis (estimated intervention effect) for
the review will be based on all studies, regardless of risk
of bias, but presented with a description of the risk of
bias in individual domains.
We will provide a narrative synthesis of the findings
from the included studies, based on the framework re-
ported by Popay et al. [28]. Separate narratives will be pre-
sented for each lifestyle domain: tobacco, alcohol, illicit
drugs, sleep, physical activity, and healthy eating. We will
describe the theoretical basis of the interventions for
included studies, which includes discussion about what
works, for whom, and why. We will provide summaries of
intervention effects in a tabular form, using data from the
extraction phase, organized according to primary outcome
for that lifestyle domain, and other reported outcomes at
all reported timepoints. We will also report on studies in
each lifestyle area according to the type of intervention
(single, multi-focus, eHealth), target population character-
istics (including phase of bipolar disorder), type of out-
come (including objective, self-report, clinician-rated),
intervention content, and the phase of BD in which the
intervention was delivered (manic/hypomanic, depressed,
euthymic). We will calculate and report risk ratios (for
dichotomous outcomes such as abstinence from tobacco)
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or standardized mean differences (for continuous outcomes
such as minutes of physical activity). Forest plots will be
generated for the primary outcome in each lifestyle area.
Where there are two or more randomized controlled
trials in a particular lifestyle area, we will carry out a meta-
analysis of primary outcome using these studies. We an-
ticipate that there will be limited scope for meta-analysis
across all lifestyle domains. The exception may be for
smoking cessation where there is likely to be a larger pool
of completed studies in BD. The meta-analysis will build
on the narrative synthesis in the eligible lifestyle area by
combining primary outcomes across studies to provide an
overall summary estimate of effect of the lifestyle interven-
tion. Both fixed and random effects models will be applied,
stratified by study size, and overall summary estimates of
effect added to the forest plots for that lifestyle area.
In interpreting the results of the analysis, the Grading
of Recommendations Assessment, Development, and
Evaluation system (GRADE) will be applied to determine
the quality of evidence for each intervention target re-
ported in the review [29]. The GRADEpro [30] program
will be used to facilitate this analysis. We will use the
following in grading the quality of the evidence arising
from the systematic review for each of the intervention
targets in bipolar disorder:
a) High = further research is very unlikely to change
our confidence in the estimate of effect.
b) Moderate = further research is likely to have an
important impact on our confidence in the estimate
of effect and may change the estimate.
c) Low = further research is very likely to have an
important impact on our confidence in the estimate
of effect and is likely to change the estimate.
d) Very low = any estimate of effect is very uncertain.
Discussion
In the general population, eliminating health risk behav-
iors has the potential to prevent 80 % of heart disease,
stroke, 80 % of type 2 diabetes, and 40 % of cancers [31].
The same is likely to be true in mental illness. Given the
complex nature of bipolar disorder, uncertainty exists
about the most effective way to drive improvements in
health behaviors, as treatments effective in other popula-
tions may not directly and safely translate to this patient
population [13]. The planned review will synthesize and
evaluate the available evidence regarding the behavioral or
psychosocial treatment of lifestyle-related behaviors in
people with BD. From this review, we will identify gaps in
our existing knowledge and research evidence about the
management of unhealthy lifestyle behaviors in people
with BD. We will also identify potential opportunities to
address lifestyle behaviors in BD, with a view to reducing
the burden of physical ill-health in this population.
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